News & Views | Telix Pharmaceuticals Limited

Notice of General Meeting

Telix today announces a general meeting of shareholders to be held at The Wesley Conference Centre, Lyceum Room, 220 Pitt Street, Sydney, NSW 2000 and online via https://meetings.linkgroup.com/TLXGM24 on Friday 5 April 2024 at 10.00am (Sydney time).

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

Telix today announces its financial results for the financial year ended 31 December 2023.

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Telix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Telix Full Year Results 2023 Investor Webcast Notification

Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February 2024.

Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update

Telix today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San Francisco.

Appointment of Dr David Cade to Group Chief Medical Officer

Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (Zircaix™, 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC).

Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

Telix Group Chief Medical Officer, Dr Colin Hayward, moderated an expert discussion with global key opinion leaders on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody drug conjugate (rADC), TLX591 (177Lu-rosopatamab tetraxetan).

Telix to Host Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

Telix today advises it will host an investor webcast on Tuesday, 21 November 2023, from 10.15am – 11.15am AEDT (12:15am CET / 6.15pm EST, 20 November). Telix Group Chief Medical Officer, Dr Colin Hayward, will moderate an expert discussion with global key opinion leaders listed below on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody drug conjugate (rADC), TLX591 (177Lu-rosopatamab tetraxetan).